← Oncology Approval Tracker

FDA DECISION ·

Penpulimab-kcqx

penpulimab-kcqx · Akeso Biopharma

FDA approvalNew therapyNasopharyngeal carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

As monotherapy for adults with metastatic non-keratinizing nasopharyngeal carcinoma after progression on or after platinum-based chemotherapy and at least one additional treatment line.

LAMPGEN ANALYSIS

Why it matters

The same-day monotherapy approval addresses a later, more heavily treated metastatic population.

What research teams should watch

Verify both prior platinum and an additional line, and recognize that the supporting single-agent study came from one country.

PRIMARY RECORDS

Sources